NCNA · NuCana plc
AI read · Good for NCNA
The AI's read
The stronger blocking of a cancer-cell process gives NuCana a possible new use for NUC-7738. The lab work points to cancers beyond multiple myeloma. But lab results do not show that the combination helps people. NuCana plans to share final results from its NUC-7738 and pembrolizumab study in December 2026.